Journal Logo

Department: DRUG CHALLENGE

Oncology drugs

Bridgeman, Mary Barna PharmD, BCPS, BCGP; Dalal, Kavitha S. PharmD

Author Information
doi: 10.1097/01.NURSE.0000743300.01640.b8
  • Free

In Brief

CAN YOU IDENTIFY these medications for oncologic disorders? To find out, match each brand name in Section I with its generic name in Section II.

Section I

______ 1. Enhertu (Daiichi Sankyo, Inc.)

______ 2. Polivy (Genentech, Inc.)

______ 3. Padcev (Astellas Pharma)

Section II

a. fam-trastuzumab deruxtecan-nxki. This drug is used to treat unresectable or metastatic human epidermal growth factor receptor 2- (HER2-) positive breast cancer in adults who had previously received two or more anti-HER2-based regimens to treat metastatic disease. It is also indicated for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. The label includes a boxed warning about the risks of interstitial lung disease, pneumonitis, and fetal harm.

b. polatuzumab vedotin-piiq. Classified as a CD79b-directed antibody–drug conjugate, this drug is indicated to treat adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior therapies. It is administered as an I.V. infusion every 21 days for six cycles in combination with bendamustine and a rituximab product. Patients should be premedicated with an antihistamine and antipyretic 30 to 60 minutes before the infusion starts and receive prophylaxis for Pneumocystisjiroveci pneumonia and herpesvirus.

c. enfortumab vedotin-ejfv. Infused over 30 minutes, this drug is indicated to treat locally advanced or metastatic urothelial cancer in adults who have previously received a programmed death receptor-1 or programmed death-ligand 1 inhibitor and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting. Severe cutaneous adverse reactions have occurred. It is not recommended for use in patients with moderate or severe hepatic impairment.

Answers: 1a, 2b, 3c

Wolters Kluwer Health, Inc. All rights reserved